Galantamine for dementia due to Alzheimer's disease and mild cognitive impairment
En una revisión Cochrane de 21 ensayos clínicos —más de 10 900 participantes (edad media 74 años)— se evidenció que la galantamina (16–24 mg/día) ralentiza significativamente el deterioro cognitivo (mejora media de –2,86 puntos en ADAS cog a los seis meses), funcional (ganancia de +2,12 puntos en DA...
Shranjeno v:
| Glavni avtor: | |
|---|---|
| Drugi avtorji: | |
| Format: | Knjiga |
| Jezik: | španščina angleščina |
| Teme: | |
| Online dostop: | Enlace web Path |
| Oznake: |
Brez oznak, prvi označite!
|
Podobne knjige/članki: Galantamine for dementia due to Alzheimer's disease and mild cognitive impairment
- Combined home-delivered transcranial direct current stimulation and cognitive training in older adults with mild cognitive impairment due to Alzheimer’s disease: a randomized, single-blind, sham-controlled trial
- Supplementation and Mitigating Cognitive Decline in Older Adults With or Without Mild Cognitive Impairment or Dementia: A Systematic Review
- Type of memory and emotional valence in healthy aging, mild cognitive impairment, and Alzheimer’s disease
- PATTERNS OF MOTOR IMPAIRMENT IN NORMAL AGING, MILD COGNITIVE DECLINE, AND EARLY ALZHEIMER'S DISEASE
- Nonpharmacological therapies for behavioral and cognitive symptoms of mild cognitive impairment
- Mild cognitive impairment in Parkinson's disease